← Leaderboards
Adam P Bress
Utah State Higher Education System--University Of Utah
$8,933,729
Attributed
$16,708,749
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.1M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,708,749 · 8
By mechanism
R01$15,069,878 · 4
K01$786,569 · 1
K24$594,639 · 1
T32$190,163 · 1
R13$67,500 · 1
Top collaborators
- Jordana B. Cohen6 shared
- Andrew Edward Moran4 shared
- William S Weintraub4 shared
- Jasmeer P Chhatwal1 shared
- Jeremy Joseph Pruzin1 shared
- Kevin M Watt1 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Chittaranjan Behera$364,561
- Anna R. Docherty$4,251,882
- Jeremy Joseph Pruzin$1,929,922
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposHypertensionPharmaceutical PreparationsPublic HealthEventAffectRegimenBlood PressureDesignAngiotensin-Converting Enzyme InhibitorsPreventAntihypertensive AgentsGuidelinesCardiovascular DiseasesS Disease Related DementiaIncidenceRandomized TrialCognitiveHealth BenefitAngiotensin Ii ReceptorPharmacoepidemiologyAgingMortalityPrevalence
Grant awards (26)
Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the racially and ethnically diverse SPRINT trial$5,789,766
R01 · FY2025 · AG · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$741,675
R01 · FY2025 · AG
Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.$198,213
K24 · FY2025 · AG · contact PI
Utah Pediatric Clinical Pharmacology Training Program$190,163
T32 · FY2025 · HD
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$167,518
R01 · FY2025 · AG
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$763,579
R01 · FY2024 · AG
Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.$198,213
K24 · FY2024 · AG · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$83,579
R01 · FY2024 · AG
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$774,072
R01 · FY2023 · AG
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens$671,017
R01 · FY2023 · AG · contact PI
Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.$198,213
K24 · FY2023 · AG · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$808,711
R01 · FY2022 · AG
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens$673,762
R01 · FY2022 · AG · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$762,748
R01 · FY2021 · HL
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens$671,692
R01 · FY2021 · AG · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$775,853
R01 · FY2020 · HL
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens$698,716
R01 · FY2020 · AG · contact PI
Genetic ancestry and antihypertensive medication responses in African Americans$124,441
K01 · FY2020 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$794,534
R01 · FY2019 · HL
Genetic ancestry and antihypertensive medication responses in African Americans$165,532
K01 · FY2019 · HL · contact PI
2019 University of Utah Translational Hypertension Symposium$30,000
R13 · FY2019 · HL · contact PI
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)$892,656
R01 · FY2018 · HL
Genetic ancestry and antihypertensive medication responses in African Americans$165,532
K01 · FY2018 · HL · contact PI
The University of Utah Translational Hypertension Symposium$37,500
R13 · FY2018 · HL · contact PI
Genetic ancestry and antihypertensive medication responses in African Americans$165,532
K01 · FY2017 · HL · contact PI
Genetic ancestry and antihypertensive medication responses in African Americans$165,532
K01 · FY2016 · HL · contact PI